Skip to Main Content

Paper Details

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Blood Cancer J
49
2022
AML, AML cells, BCL2, CDK6, FLT3 mutation, HOXA9, MEIS1, MLL, MLL rearrangement, MLL1, MLL1-FP, MLL1-fusion protein, MLL1-r, MLL1-r AML cells, Menin, NPM1, NPM1 mutation, NPM1c, PD, PD AML, SNDX-50469, SNDX-5613, abemaciclib, cell line, cell lines, mt-, mt-NPM1, mtNPM1, mtTP53, mutant (mt)-NPM1, patient, patients, venetoclax
Author NameAffiliation
Courtney D DiNardoThe University of Texas M.D. Anderson Cancer Center
Yuan QiThe University of Texas M.D. Anderson Cancer Center
Gerard M McGeehanSyndax Pharmaceuticals, Inc.
Benjamin L EbertHoward Hughes Medical Institute, Dana-Farber Cancer Institute
  • 1 - 4

Datasets

Release 1.2